Inovio Pharma (INO) Misses Q2 EPS by 14c
Tweet
Share
E-mailGet Alerts INO Hot Sheet
Price: $9.86 -2.95%
Revenue Growth %: +490.9%
Financial Fact:
Net loss/ (gain) attributable to non-controlling interest: 0
Today's EPS Names:
FRSB, DGICA, UXIN, More
Revenue Growth %: +490.9%
Financial Fact:
Net loss/ (gain) attributable to non-controlling interest: 0
Today's EPS Names:
FRSB, DGICA, UXIN, More
Join SI Premium – FREE
Inovio Pharma (NASDAQ: INO) reported Q2 EPS of ($0.39), $0.14 worse than the analyst estimate of ($0.25). Revenue for the quarter came in at $273 thousand versus the consensus estimate of $1.21 million.
For earnings history and earnings-related data on Inovio Pharma (INO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises
- Esquire Financial Holdings, Inc. (ESQ) Tops Q1 EPS by 3c
- Ladder Capital (LADR) Tops Q1 EPS by 4c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
